Improving endocrine therapy for breast cancer: it's not that simple.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.Breast cancer research and treatment · 2014
   Trial
2. Unbiased niche labeling maps immune-excluded niche in bone metastasis.Cell · 2026
   Article
3. Targeting Metabolic Adaptations in the Breast Cancer-Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy.Molecular cancer research : MCR · 2022
   Article
4. Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.Exploration of targeted anti-tumor therapy · 2022
   Review
5. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities ofCancer research · 2021
   Article
6. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.Journal of hematology & oncology · 2019
   Article
7. Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance.Cancers · 2019
   Article
8. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.Journal of hematology & oncology · 2018
   Article
9. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.Breast cancer research : BCR · 2016
   Review
10. Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research.Journal of translational medicine · 2016
    Review
11. Cooperative Dynamics of AR and ER Activity in Breast Cancer.Molecular cancer research : MCR · 2016
    Article
12. ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.Molecular endocrinology (Baltimore, Md.) · 2016
    Article
13. COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.Nature communications · 2016
    Article
14. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.Breast cancer research and treatment · 2014
    Article
15. Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population.The Pan African medical journal · 2014
    Article

Corrections and comments

• Comment on
  Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.2013

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as